RAD — Radiopharm Theranostics Share News
0.000.00%
Last trade - 00:00- AU$15.95m
- AU$9.45m
- AU$2.77m
Brief: Radiopharm Theranostics Announce Expanded Agreement With Terthera To Supply Terbium-161
Brief: Radiopharm Theranostics Says Positive Guidance From FDA Pre-IND Meeting
Brief: Radiopharm Theranostics Receives FDA Orphan Drug Designation For Trivehexin (Rad 301) In Pancreatic Cancer
Brief: Radiopharm Theranostics Says U.S. FDA Granted Orphan Drug Designation To GA68-TRIVEHEXIN
Australia's Radiopharm Theranostics rises on supply agreement with Dutch firm
Brief: Radiopharm Theranostics Says It Enters Supply Agreement With TerThera
Brief: Radiopharm Theranostics Says Via Unit Entered Binding Agreement To Acquire Pharma15 Corp
Brief: Radiopharm Theranostics Posts HY Net Loss Attributable A$12.6 Million
Brief: Radiopharm Theranostics Initiates Process For Nasdaq Listing
Brief: Radiopharm Theranostics Initiates Process For Nasdaq Listing
Australia's Radiopharm Theranostics jumps on receiving U.S. FDA approval
Brief: Radiopharm Theranostics Got U.S. FDA IND Approval For Its Αvβ6 Integrin (Rad301) Technology
Brief: Radiopharm Theranostics Says Australia's Nuclear Science And Technology Organisation Deal
Brief: Radiopharm Theranostics Signs Agreement With Northstar Medical Radioisotopes For The Supply Of Non-Carrier Added Actinium-225
Brief: Radiopharm Theranostics Says Entered Into Clinical Supply Agreement
Brief: Radiopharm Theranostics Announces Entitlement Offer To Raise Up To A$10 Mln
Brief: Radiopharm Theranostics Seeks Trading Halt
Brief: Radiopharm Theranostics Says U.S. FDA Grants Rare Pediatric Disease Designation For Dunp19
Australia's Radiopharm Theranostics soars on FDA nod for osteosarcoma treatment